What is Biofortuna?
Biofortuna operates as a premier contract development and manufacturing organization (CDMO) with a specialized focus on assay development, cell line quality control, and comprehensive laboratory services. The company provides essential technical support, including molecular and immunoassay development, lyophilisation, and controlled storage solutions. By leveraging state-of-the-art facilities, Biofortuna effectively mitigates technical risks for its clients, thereby accelerating the speed to market for high-stakes diagnostic innovations. Its market position is defined by a commitment to quality and precision, serving as a vital link in the life sciences supply chain for organizations requiring tailored, high-compliance laboratory support.
How much funding has Biofortuna raised?
Biofortuna has raised a total of $14.9M across 7 funding rounds:
Other Financing Round
$1.6M
Other Financing Round
$2M
Other Financing Round
$3.3M
Unspecified
$2M
Unspecified
$2.3M
Unspecified
$1.6M
Unspecified
$2.1M
Other Financing Round (2010): $1.6M with participation from Enterprise Ventures and Catapult Ventures
Other Financing Round (2012): $2M led by Merseyside Special Investment Fund, Catapult Ventures, Enterprise Ventures, and Foresight Group
Other Financing Round (2012): $3.3M supported by Merseyside Special Investment Fund, Foresight Group, and Catapult Ventures
Unspecified (2013): $2M featuring Enterprise Ventures, Merseyside Special Investment Fund, Catapult Ventures, and Foresight Group
Unspecified (2015): $2.3M backed by Merseyside Special Investment Fund, Enterprise Ventures, Foresight Group, and Catapult Ventures
Unspecified (2016): $1.6M with participation from Catapult Ventures and EV Tech
Unspecified (2017): $2.1M, investors not publicly disclosed
Key Investors in Biofortuna
Catapult Ventures
Catapult Ventures specializes in providing tailored investment solutions to meet the funding needs of entrepreneurs and business owners, focusing on unlocking potential and fostering long-term value through strategic partnerships.
Merseyside Special Investment Fund
MSIF is dedicated to empowering small and medium-sized enterprises in the Liverpool City Region by offering alternative finance solutions and business support to foster regional innovation and economic growth.
Enterprise Ventures
Enterprise Ventures operates within the investment banking sector, providing critical capital and financial expertise to support the growth and development of emerging businesses.
What's next for Biofortuna?
With the recent influx of capital, Biofortuna is well-positioned to enhance its service capabilities and expand its operational footprint. The strategic focus will likely center on scaling its lyophilisation and assay development infrastructure to meet the increasing demand from global life science innovators. As the diagnostic sector continues to prioritize rapid, high-quality development cycles, Biofortuna's ability to provide integrated, risk-mitigated solutions will be a key driver of its future market share. The company is expected to leverage this financial backing to further optimize its laboratory workflows and strengthen its competitive advantage in the high-growth CDMO market.
See full Biofortuna company page
